MapLight Therapeutics, Inc.·4

Oct 30, 4:31 PM ET

Novo Holdings A/S 4

4 · MapLight Therapeutics, Inc. · Filed Oct 30, 2025

Insider Transaction Report

Form 4
Period: 2025-10-28
Novo A/S
10% Owner
Transactions
  • Conversion

    Voting Common Stock

    2025-10-28+2,733,6812,733,681 total
  • Conversion

    Series D Preferred Stock

    2025-10-2819,734,6710 total
    Voting Common Stock (1,174,682 underlying)
  • Purchase

    Voting Common Stock

    2025-10-28$17.00/sh+952,941$16,199,9973,686,622 total
  • Conversion

    Series C Preferred Stock

    2025-10-2826,191,2070 total
    Voting Common Stock (1,558,999 underlying)
Footnotes (2)
  • [F1]The Series C Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.
  • [F2]Represents a purchase from the underwriters in the Issuer's initial public offering.

Documents

1 file
  • 4
    form4-10302025_081039.xmlPrimary